Results 121 to 130 of about 49,826 (161)
Some of the next articles are maybe not open access.
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets, 2018Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and ...
Ceylan, Asli F., Ren, Sidney Y.
openaire +3 more sources
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Expert Opinion on Emerging Drugs, 2013Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire +2 more sources
Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
Journal of Diabetes and its Complications, 2016Diabetic ketoacidosis is a serious metabolic condition that may occur in patients with either Type 1 or Type 2 diabetes. The accumulation of ketoacids in the serum is a consequence of insulin deficiency and glucagon excess. Sodium Glucose Transporter 2 (SGLT2) inhibitors are novel therapeutic treatments for improving glucose homeostasis in patients ...
Biff F, Palmer +3 more
openaire +2 more sources
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
Clinical Nephrology, 2017Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou +2 more
openaire +2 more sources
Sodium-Glucose Co-Transport Inhibitors
Drugs, 2010The kidney plays a major role in glucose homeostasis because of its role in gluconeogenesis and the glomerular filtration and reabsorption of glucose in the proximal convoluted tubules. Approximately 180 g of glucose is filtered daily in the glomeruli of a normal healthy adult. Typically, all of this glucose is reabsorbed with
Joshua J, Neumiller +2 more
openaire +2 more sources
Sodium-glucose-linked transporter 2 inhibitors from Sophora flavescens
Medicinal Chemistry Research, 2014During the screening of a prefractionated natural product extract library (400 biota) against sodium-glucose-linked transporter 2 (SGLT2), a methanol fraction of the traditional Chinese medicine, Sophora flavescens, displayed promising inhibitory activity against SGLT2.
Jing Yang +5 more
openaire +1 more source
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
Expert Opinion on Therapeutic Patents, 2012Maintenance of glucose homeostasis in healthy individuals involves SGLT2 (sodium glucose co-transporter 2)-mediated recovery of glucose from the glomerular filtrate which otherwise would be excreted in urine. Clinical studies indicate that SGLT2 inhibitors provide an insulin-independent means to reduce the hyperglycemia that is the hallmark of type 2 ...
openaire +2 more sources
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources